Dennis Harris, PhD, Joins IntegenX as Chief Scientific Officer

PLEASANTON, CA--(Marketwire - March 01, 2011) - IntegenX today announced that Dennis Harris, PhD, a leader in the field of biotechnology science innovation, has been appointed as Chief Scientific Officer (CSO). As CSO, Dr. Harris will lead the technology development program at IntegenX and direct the company's scientific research, collaborations, and grants and contracts strategies.

Dr. Harris is a co-founder of IntegenX and has served as a board member since 2003. Dr. Harris began his scientific career at Amersham International, developing commercial molecular biology kits and reagents, including products required for bead-based methods in automated DNA processing systems and for DNA sequencing. At Amersham Pharmacia Biotech, now part of GE, Dr. Harris served as project manager for the MegaBACE™ system, the first commercial capillary array-based DNA sequencing and genotyping product. After the successful market introduction of MegaBACE, he became Vice President of Research and Development for the North American division of Amersham Pharmacia Biotech. Dr. Harris then served as Senior Vice President of R&D at Aclara Biosciences, which was the leading developer of plastic microfluidic devices for life science analytics. In 2004, he joined Serologicals Corporation as Vice President and Chief Scientific Officer. Upon Serological's acquisition by Millipore Corporation in 2006, he became CSO of Millipore until December 2010, after the close of its acquisition by Merck KGaA.

"Dr. Harris, a co-founder of IntegenX, adds a deep understanding of the assessment, acquisition, and development of leading edge life science and medical technologies to their full commercial potential. Dennis has identified numerous instrument and reagent platforms and has been instrumental in taking them to commercial market success," said Stevan Jovanovich, PhD, co-founder, President and Chief Executive Officer of IntegenX. "His expertise will help IntegenX create and sustain market leadership for genomic sample preparation and sample-to-answer solutions for multiple applications."

About IntegenX Inc.
IntegenX Inc., headquartered in Pleasanton, CA, is a privately held company that designs, manufactures, and markets automated genomic sample preparation systems for life sciences, applied sciences, and diagnostics markets. IntegenX products eliminate the most acute pain points affecting widely adopted laboratory genomic workflows. The company's expertise and intellectual property includes its patented MOVe™ valve technology, proprietary patent-pending PrepX™ reagent kits, and systems integration. The MOVe microfluidics technology platform integrates advanced fluidics and robotic capabilities to prepare samples for DNA and RNA sequencing and to produce an automated sample-to-answer system for DNA-based human identity (HID) testing and an integrated sample-to-Next Generation Sequence system for biodefense and molecular diagnostics applications. For more information, please visit www.integenx.com.